/ /

Cheryl Guttman Krader
No one imaging tool fits all in identifying AMD lesions
Multimodal imaging, including traditional and newer techniques, is necessary for identifying the spectrum of retinal lesions associated with age-related macular degeneration (AMD), said David Sarraf, MD.
DARPin molecule prolongs anti-VEGF activity in nAMD
A phase III study program investigating abicipar pegol (Allergan) for the treatment of neovascular age-related macular degeneration (nAMD) is underway based on promising efficacy and safety results in phase II studies.
Treating ROP: Laser associated with high success rate for retinopathy of prematurity
Laser photocoagulation is a time-tested, well-defined, and effective treatment for retinopathy of prematurity (ROP) with requirements for follow-up that are much more manageable compared with anti-vascular endothelial growth factor (anti-VEGF) therapy, argued David K. Wallace, MD, MPH.
Treating ROP: Substantial benefits make anti-VEGF preferred for Zone I disease
Anti-VEGF therapy for Zone I retinopathy of prematurity (ROP) is associated with better structural and functional outcomes than laser therapy, but also a longer recurrence risk period, said Helen A. Mintz-Hittner, MD.
Insights from anti-VEGF pivotal DME trials
Analyses of data collected in the RISE/RIDE and VIVID/VISTA clinical trials provide important messages about the efficacy and safety of ranibizumab (Lucentis, Genentech) and aflibercept (Eylea, Regeneron) for treatment of diabetic macular edema (DME).
Innovator in small pupil management recognized with Binkhorst Medal
At the 2006 ASCRS Film Festival, Dr. Malyugin, professor of ophthalmology and deputy director, S. Fyodorov Eye Microsurgery Institution, Moscow, received the first-place award in the instruments/devices category for his video, “Russian solution to small-pupil phaco and tamsulosin floppy-iris syndrome,” that presented the pupil expansion ring he designed for atraumatic management of the small pupil.